This startup provides an AI-powered drug discovery platform that accelerates early-stage research by offering a screening and scoring tool. This platform helps pharmaceutical companies reduce the time and resources needed to identify and develop new drug candidates.
Funding
$443.8K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods are slow, expensive, and limited by the size and diversity of available chemical libraries, hindering the identification of novel drug candidates. Existing in silico virtual screening approaches often require computationally intensive 3D conformational sampling and lack the speed and accuracy needed to efficiently explore the vast chemical space.
Solution
ANYO Labs offers i-TripleD, an AI-powered drug discovery platform that accelerates the identification of biologically active small molecules. i-TripleD leverages machine learning and proprietary technologies to overcome bottlenecks in virtual screening, enabling rapid and accurate evaluation of vast chemical spaces without the need for 3D conformational sampling. The platform integrates a de novo molecular generator (iGen) that can generate and filter compounds on the fly, or screen external molecular libraries. ANYO Labs' AI-based scoring function (iScore) facilitates ultra-fast screening, while a filtration module (iClass) reduces false positives.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and drug discovery organizations seeking to accelerate early-stage drug discovery and reduce the time and cost associated with identifying promising drug candidates.
Features
- iGen: AI-driven generative module for de novo drug molecule generation, producing >2000 molecules per second.
- iScore: AI-based scoring function that bypasses 3D conformational sampling for ultra-fast screening.
- UFS (Ultra-Fast Screening): Enables screening speeds several orders of magnitude faster than current tools.
- iClass: Filtration module to reduce false positives in virtual screening.
- ADMET predictions: State-of-the-art ML-based tool for assessing drug metabolism and toxicity with >86% accuracy across 41 assays.
- Synthetic feasibility module: Provides an overview of the synthetic feasibility of hit compounds.
- Benchmarked against gold standard test sets (PDBbind 2016, CSAR NRC-HiQ Set1/2, CASF-2016) for scoring, ranking, and screening power.